Business Wire

3D Systems Achieves Full-Scope EU MDR Certification, Accelerating European Launch of NextDent® Jetted Denture Solution Targeted for Summer 2026

25.3.2026 17:20:00 CET | Business Wire | Press release

Share

Certification Marks Major Milestone in Strategic Dental Growth Initiative Addressing Straightening, Protection, Repair and Replacement of Teeth

3D Systems (NYSE: DDD) today announced it has received full-scope certification under the European Union Medical Device Regulation (EU MDR) 2017/745. The certification was attained on Monday, March 16, 2026.

This milestone confirms that the Company’s quality system, technical documentation, and clinical evidence meet the most rigorous regulatory requirements in the medical device sector. With the MDR certificate in hand, 3D Systems will now introduce MDR-compliant product versions through a carefully coordinated, phased rollout across its dental product families and European markets. This approach ensures a smooth transition while maintaining uninterrupted product availability for customers and healthcare providers.

The EU MDR certification immediately enables the introduction of innovative new materials and is a pivotal step for one of 3D Systems’ largest potential new product launches: the NextDent® Jetted Denture Solution. This solution forms the cornerstone of the Company’s ‘replacement’ offering within its comprehensive digital dentistry strategy, which spans applications for straightening, protection, repair, and full replacement of teeth.

Building on the successful U.S. commercial launch in 2025, this European rollout positions 3D Systems to capture additional share in a substantial global opportunity. According to the Company’s internal estimates, applications for the ‘replacement’ pillar of its dental strategy represent an addressable market of approximately $600 million in the United States alone by 2029, with the U.S. comprising roughly one-third of the total global market. The market in the EU is estimated to be comparable, or even slightly larger in scale than that of the U.S., based on Company analysis and demographic trends. As highlighted by President and CEO, Dr. Jeffrey Graves, during the Company’s Q4 2025 earnings call on March 9, 2026, approximately 32 million people in the United States wear dentures, roughly 10% of the population, and globally more than 180 million people wear dentures, driving annual production of approximately 13.7 million denture sets. Management further noted that 3D Systems’ materials alone represent a potential annual recurring revenue opportunity of more than $400 million globally over time, as digital manufacturing adoption accelerates.

The European launch of NextDent Jetted Dentures remains firmly on track for summer 2026.

3D Systems has long held a leadership position in digital dentistry, particularly in orthodontic aligner production.

Through its longstanding partnership with major industry players and the deployment of application specific high-volume manufacturing stereolithography (SLA) technology, the Company’s solutions enable the manufacture of approximately one million patient-specific clear aligners daily worldwide, establishing it as a key enabler in the straightening segment of the market.

This leadership builds on the 2017 acquisition of Vertex Global Holding B.V., which brought together Vertex Dental’s decades-long legacy in high-quality prosthetic dental materials (dating back to its founding in 1939) with NextDent’s pioneering biocompatible 3D printing resins. NextDent, originally launched in 2012 to advance materials for emerging 3D printing innovations in dentistry, has since developed one of the industry’s broadest portfolios of clinically validated, regulatory-approved materials, addressing applications from models and surgical guides to splints, crowns, bridges, and dentures. The integration of these advanced Vertex and NextDent materials with 3D Systems’ printing platforms has driven transformative efficiency, precision, and cost reductions across dental workflows.

“Receiving full-scope EU MDR certification validates our commitment to the highest standards of quality and patient safety while unlocking significant new growth opportunities across the European dental market,” said Jeffrey Graves, President and Chief Executive Officer of 3D Systems. “Building on our established dominance in high-volume aligner production and the industry-leading NextDent materials portfolio from our Vertex acquisition, the NextDent Jetted Denture Solution represents a transformative advancement in delivering monolithic, multi-material prosthetics with superior aesthetics, durability, and production efficiency using our MultiJet Printing technology. With strong early traction in the U.S. and the substantial addressable market we outlined in our recent earnings call, this launch accelerates momentum in our dental business, one of our most significant growth initiatives, and reinforces its role as a key driver of long-term shareholder value. We are excited about these accomplishments and the substantial business opportunities they generate.”

Powered by the NextDent 300 MultiJet 3D printer and specialized NextDent Jet Base and Teeth materials, the solution enables dental labs to produce durable, aesthetically superior, one-piece dentures far faster and more cost-effectively than traditional analog methods. This delivers both outstanding patient outcomes and strong return on investment for labs and clinicians.

This regulatory achievement further solidifies 3D Systems’ leadership position in digital dentistry and supports the Company’s broader strategic initiatives to expand in high-value healthcare applications.

About 3D Systems For nearly 40 years, Chuck Hull’s curiosity and desire to improve the way products were designed and manufactured gave birth to 3D printing, 3D Systems, and the additive manufacturing industry. Since then, that same spark continues to ignite the 3D Systems team as we work side-by-side with our customers to change the way industries innovate. As a full-service solutions partner, we deliver industry-leading 3D printing technologies, materials and software to high-value markets such as medical and dental; aerospace, space and defense; transportation and motorsports; AI infrastructure; and durable goods. Each application-specific solution is powered by the expertise and passion of our employees who endeavor to achieve our shared goal of Transforming Manufacturing for a Better Future. More information on the Company is available at www.3dsystems.com.

Forward-Looking Statements Certain statements in this press release are forward-looking, including statements regarding the timing of product launches, regulatory timelines, market opportunities, and the expected impact on growth and shareholder value. Actual results may differ materially due to risks and uncertainties detailed in the Company’s SEC filings. 3D Systems undertakes no obligation to update any forward-looking statements.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260325055174/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 07:10:00 CEST | Press release

Collaboration will connect seamless payments, in-app digital engagement and AI-powered travel services to enhance the visitor journey, empower businesses of all sizes and unlock wider cross-border commerce opportunities Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Mal

PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 07:00:00 CEST | Press release

Patient-reported outcomes from a phase II study of nemolizumab in children aged 2 to 11 with moderate-to-severe atopic dermatitis show meaningful reductions in itch severity, better sleep and improved quality of life, maintained for a year1 Currently, there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis, despite the high unmet need – the disease can significantly reduce quality of life for children and create burden on their families2-8 These findings expand on the clinical evidence base for nemolizumab, which has multiple global approvals for adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis, and adults with prurigo nodularis9,10 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe

Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 02:30:00 CEST | Press release

− ORZEYFUL is now available in Japan and China following approvals within a month of each other by China’s National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labour and Welfare (MHLW) − Discovered by Takeda scientists in Japan, ORZEYFUL is the lead medicine in Takeda’s orexin franchise, with multiple programs for sleep-wake disorders and conditions where orexin biology plays a role − ORZEYFUL set to launch next month in the U.S., following completion of DEA scheduling; Health Authority submissions underway worldwide Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re ex

Celltrion to Spotlight Subcutaneous (SC) Infliximab (Remsima™ SC) and Broader IBD Portfolio at UEG Week 202615.10.2026 02:10:00 CEST | Press release

Celltrion to showcase its broad IBD portfolio, including Remsima™ IV, Remsima™ SC, the newly launched Remsima™ IV Liquid formulation, Steqeyma™ and Yuflyma™Symposium and Meet the Experts sessions to highlight long-term clinical evidence and real-world experience with subcutaneous (SC) infliximab (Remsima™ SC) across different IBD patient scenarios Celltrion, Inc. (KRX:068270) announced its participation in United European Gastroenterology (UEG) Week 2026, in Barcelona, Spain (Oct. 17-20), highlighting its inflammatory bowel disease (IBD) treatment portfolio, led by Remsima™ SC (subcutaneous infliximab). Celltrion will showcase its comprehensive infliximab portfolio, comprising Remsima™ intravenous (IV) and subcutaneous (SC) formulations, as well as the Remsima™ IV liquid formulation launched in Europe earlier this year.1 Additionally, the company will highlight its broader IBD portfolio, including SteQeyma™ (ustekinumab) and Yuflyma™ (adalimumab), reflecting its continued efforts to ex

ProcureTEX Returns for Its Second Year, Bringing AI and Best-of-Breed Procurement Technology to Amsterdam14.10.2026 18:26:00 CEST | Press release

Founding partners Beroe, Keelvar and Zip bring back the community-driven event with a practitioner-shaped agenda spanning real-world AI use and the future of procurement ProcureTEX, the community-driven event for best-of-breed procurement technology, returns for its second year on November 3, 2026, at Circa in Amsterdam. Following its London debut in 2025, the event sharpens its focus on how AI is reshaping procurement. It will bring together over 250 procurement leaders and digital transformation teams from large enterprises, with vetted best-of-breed technology providers, to see AI agents and interoperable tools working together on real enterprise challenges. Co-founded by Beroe, Keelvar and Zip, the event is built on the belief that the future of procurement isn’t a monolithic all-in-one suite, but an ecosystem of best-of-breed tools working together. It is designed for procurement and enterprise leaders seeking scalable, modern solutions, whether they’re driving transformation, fru

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye